Market Closed -
Euronext Bruxelles
11:35:17 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.018
EUR
|
-9.09%
|
|
-14.29%
|
-23.40%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
46.49
|
29.89
|
6.83
|
4.86
|
4.904
|
82.82
|
Enterprise Value (EV)
1 |
44.83
|
23.54
|
8.407
|
7.664
|
7.64
|
93.38
|
P/E ratio
|
-3.88
x
|
-1.9
x
|
-0.41
x
|
-3.57
x
|
1.26
x
|
-14.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
77
x
|
52.7
x
|
6.31
x
|
13.5
x
|
11,817
x
|
2.24
x
|
EV / Revenue
|
74.2
x
|
41.5
x
|
7.77
x
|
21.4
x
|
18,409
x
|
2.52
x
|
EV / EBITDA
|
-3.81
x
|
-1.88
x
|
-0.54
x
|
-14.9
x
|
1.96
x
|
-45.4
x
|
EV / FCF
|
-6.71
x
|
-2.93
x
|
-1.22
x
|
-7.32
x
|
-4.31
x
|
-142
x
|
FCF Yield
|
-14.9%
|
-34.2%
|
-82.2%
|
-13.7%
|
-23.2%
|
-0.71%
|
Price to Book
|
38.8
x
|
4.88
x
|
-1.64
x
|
-0.86
x
|
-2.84
x
|
7.84
x
|
Nbr of stocks (in thousands)
|
12,806
|
18,397
|
21,893
|
21,893
|
21,893
|
1,489,607
|
Reference price
2 |
3.630
|
1.625
|
0.3120
|
0.2220
|
0.2240
|
0.0556
|
Announcement Date
|
4/17/18
|
5/13/19
|
5/7/20
|
4/30/21
|
4/30/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.604
|
0.567
|
1.082
|
0.3589
|
0.000415
|
37.06
|
EBITDA
1 |
-11.77
|
-12.51
|
-15.66
|
-0.5147
|
3.894
|
-2.055
|
EBIT
1 |
-11.98
|
-12.77
|
-15.95
|
-0.6317
|
3.881
|
-2.311
|
Operating Margin
|
-1,982.62%
|
-2,251.68%
|
-1,474.37%
|
-175.98%
|
935,124.1%
|
-6.24%
|
Earnings before Tax (EBT)
1 |
-11.98
|
-14.32
|
-15.66
|
-1.362
|
3.896
|
-5.584
|
Net income
1 |
-11.99
|
-14.32
|
-15.66
|
-1.362
|
3.895
|
-5.578
|
Net margin
|
-1,984.44%
|
-2,525.75%
|
-1,447.11%
|
-379.45%
|
938,554.22%
|
-15.05%
|
EPS
2 |
-0.9360
|
-0.8567
|
-0.7693
|
-0.0622
|
0.1779
|
-0.003744
|
Free Cash Flow
1 |
-6.682
|
-8.04
|
-6.913
|
-1.047
|
-1.773
|
-0.6585
|
FCF margin
|
-1,106.35%
|
-1,418.06%
|
-639.01%
|
-291.77%
|
-427,113.73%
|
-1.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/17/18
|
5/13/19
|
5/7/20
|
4/30/21
|
4/30/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
1.58
|
2.8
|
2.74
|
10.6
|
Net Cash position
1 |
1.66
|
6.35
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.1007
x
|
-5.448
x
|
0.7027
x
|
-5.136
x
|
Free Cash Flow
1 |
-6.68
|
-8.04
|
-6.91
|
-1.05
|
-1.77
|
-0.66
|
ROE (net income / shareholders' equity)
|
-167%
|
-374%
|
-1,366%
|
27.8%
|
-106%
|
-51.9%
|
ROA (Net income/ Total Assets)
|
-75.4%
|
-101%
|
-109%
|
-6.61%
|
58.1%
|
-3.79%
|
Assets
1 |
15.89
|
14.21
|
14.42
|
20.6
|
6.708
|
147.1
|
Book Value Per Share
2 |
0.0900
|
0.3300
|
-0.1900
|
-0.2600
|
-0.0800
|
0.0100
|
Cash Flow per Share
2 |
0.1700
|
0.4400
|
0.1700
|
0.1300
|
0.0600
|
0
|
Capex
1 |
0.16
|
0.37
|
0.1
|
-
|
-
|
2.21
|
Capex / Sales
|
26.66%
|
65.43%
|
8.97%
|
-
|
-
|
5.96%
|
Announcement Date
|
4/17/18
|
5/13/19
|
5/7/20
|
4/30/21
|
4/30/22
|
4/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -23.40% | 28.62M | | -17.89% | 8.25B | | +39.20% | 3.58B | | -39.11% | 2.46B | | -8.06% | 2.46B | | -7.35% | 2.38B | | -19.01% | 1.55B | | -40.66% | 1.21B | | +7.56% | 1.11B | | -15.34% | 1.03B |
Medical & Diagnostic Laboratories
|